title: Second primary lung cancer.
abstract: We reviewed our experience with second primary lung cancer (SPLC) at the Little Rock Veterans Affairs Medical Center from 1966 to 1993. Fifty-four patients were found to have 65 such lesions after 1,572 "curative" resections for lung cancer (4.1%). Eleven patients had at least a third primary tumor (3 having more). Metachronous SPLCs comprised 60% (39/65) and synchronous 40% (26/65). The mean interval between first and second tumors was 54.63 +/- 8 (standard error) months (range, 5 to 218 months), and that between second and third was 26.1 +/- 7.4 (standard error) (range, 5.5 to 51 months). Squamous cell carcinoma comprised 58.4% (38/65), adenocarcinoma 30.8% (20/65), and small cell carcinoma 10.8% (7/65). Histology of the SPLC was the same as that of the first tumor in 50.7% (33/65). Stage I primary tumors comprised 76% (41/54) of index tumors, 61.1% (33/54) of SPLCs, and 72.2% (8/11) of third primary tumors. Second primary lung cancer followed minimal resection in 44% (24/54), lobectomy in 37% (20/54), and pneumonectomy in 13% (7/54) of cases. There was no evidence that minimal resection for the first primary tumor predisposed to SPLC. After 1983 the majority of SPLCs were diagnosed with computed tomographic scanning. After resection of SPLCs, survival rates at 3 and 5 years were 26% and 18%, metachronous 39% and 23.4%, and synchronous 12.25% and 12.25%.
authors.affiliation: Surgical Service, John L. McClellan Memorial Veterans Hospital, Little Rock, Arkansas 72205.
authors.forename: T
authors.initials: T
authors.lastname: Antakli
authors.forename: R F
authors.initials: RF
authors.lastname: Schaefer
authors.forename: J E
authors.initials: JE
authors.lastname: Rutherford
authors.forename: R C
authors.initials: RC
authors.lastname: Read
mesh_terms: D000206:Actuarial Analysis; D000230:Adenocarcinoma / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D001131:Arkansas / Q000453:epidemiology; D018288:Carcinoma, Small Cell / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D013997:Time Factors